Reapplix APS has raised €2.7m ($3.04m) in new capital to support activities that will put the Danish firm on the path to getting that all-important reimbursement for its advanced wound-care product, LeucoPatch, before moving ahead on a full commercial launch.
The additional funding came from Reapplix’s existing investors – Novo Seeds, SEED Capital and Vækstfonden (The Danish Growth Fund) – that have been backing the Birkerød-based company since it was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?